Publication | Closed Access

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT

Hematological MalignancyBu Dose IntensityMedicineMixed-phenotype Acute LeukemiaHematologyPharmacologyFb2 Vs Fb4Myeloid NeoplasiaPharmacotherapyOncologyRadiation OncologyAllogeneic HctHealth Sciences